- Report
- June 2025
- 200 Pages
Global
From €2452EUR$2,789USD£2,136GBP
- Report
- November 2022
- 154 Pages
Global
From €4395EUR$5,000USD£3,829GBP
- Report
- November 2024
- 600 Pages
Global
From €2901EUR$3,300USD£2,527GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €879EUR$1,000USD£766GBP
€1099EUR$1,250USD£957GBP
- Report
- May 2024
- 135 Pages
Global
From €4856EUR$5,524USD£4,230GBP
€5713EUR$6,499USD£4,977GBP
- Report
- July 2023
- 290 Pages
Global
From €3165EUR$3,600USD£2,757GBP
- Report
- April 2023
- 147 Pages
Global
From €4350EUR$4,949USD£3,790GBP
- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 747 Pages
Global
From €3516EUR$4,000USD£3,063GBP
Tumor suppressor drugs are a type of oncology drug used to treat cancer. They work by inhibiting the growth of cancer cells, either by blocking the growth of new cells or by killing existing cells. Tumor suppressors are typically used in combination with other treatments, such as chemotherapy or radiation therapy, to maximize the effectiveness of the treatment. They are also used to reduce the risk of recurrence of cancer after treatment.
Tumor suppressors are typically administered orally or intravenously, depending on the type of cancer being treated. Common side effects of tumor suppressors include nausea, vomiting, fatigue, and hair loss.
The tumor suppressor market is a rapidly growing segment of the oncology drug market. As the number of cancer cases continues to rise, the demand for effective treatments is increasing. This has led to an increase in research and development of new tumor suppressor drugs, as well as the development of new delivery methods.
Some companies in the tumor suppressor market include Novartis, Merck, Pfizer, and AstraZeneca. Show Less Read more